CE Holdings Co.,Ltd.
Fiscal Year Ending September 2026 Q3 Financial Summary (Consolidated) [Japanese GAAP]
For the three-month period ended September 2026, consolidated results show net sales of approximately 13,392 million yen, operating income of approximately 1,264 million yen, ordinary income of approximately 1,384 million yen, and net income attributable to owners of the parent of approximately 685 million yen. Profit improved due to increased sales of the electronic medical record system. An accompanying earnings briefing material is available. The forecast for the year-end dividend for the fiscal year ending September 2026 has been revised to omission of dividend (possible impact from the TOB initiated by SK-03).
Key Figures
- Net Sales: 13,292百万円 (YoY +7.9%)
- Operating Income: 1,364百万円 (YoY +14.1%)
- Ordinary Income: 1,384百万円 (YoY +14.9%)
AI要約
Overview of Results
During the period, net sales increased year over year, with higher sales of the electronic medical record system contributing to profit growth. Segment-level results, including Healthcare Solutions and Marketing Solutions, remained solid in sales and profits, leading to higher operating income, ordinary income, and net income compared with the previous year. The smartphone service 'Doctor Connect' recorded impairment charges, but overall profit remained positive. Backlog trends show a decline, yet sales growth was maintained.
Outlook and Implications
Against the backdrop of government initiatives promoting medical DX, the adoption of medical information systems such as electronic medical records is expected to continue. However, potential delays in server and networking equipment delivery and rising costs due to semiconductor supply-demand imbalances and a weaker yen may affect fourth-quarter and beyond performance. The company has announced an intention to omit the year-end dividend for fiscal 2026, and the impact of the TOB requires close monitoring.
Revenue Trend
Operating Income Trend
Segment Revenue
Segment Profit Margin
CE Holdings, Inc.
Company overview · Stock price · Financial data · All IR
